AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2021
Jun 2, 2021
31580_dirs_2021-06-02_45dc193e-f013-4d8c-8641-bfeb0e985e2c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2021-05-28
Reporting Person: Schenkein David P (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-28 | Common stock | M | 1686 | — | Acquired | 114277 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-05-28 | Restricted stock units | $ | M | 1686 | Disposed | Common stock (1686.0) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common stock | 79082 | Indirect |
| Common stock | 270772 | Indirect |
Footnotes
F1: Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
F2: Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F4: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested.